nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.10.2004 | Review

Effective immunotherapy against cancer

A question of overcoming immune suppression and immune escape?

verfasst von: Karl-Johan Malmberg

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 10/2004

Einloggen, um Zugang zu erhalten

Abstract

During the last decade, the breakthroughs in understanding of the molecular mechanisms responsible for immune activation and the advent of recombinant DNA technologies have changed the view on immunotherapy from “a dream scenario” to becoming a clinical reality. It is now clear that both cellular immunity comprising T and NK cells, as well as strategies based on antibodies, can provide strong antitumoral effects, and evidence is emerging that these strategies may also cure patients with previously incurable cancers. However, there are still a number of issues that remain unresolved. Progress in immunotherapy against cancer requires a combination of new, improved clinical protocols and strategies for overcoming mechanisms of immune escape and tumor-induced immune suppression. This review discusses some of the salient issues that still need to be resolved, focusing on the role of oxidative stress and the use of antioxidants to alleviate the immune hyporesponsiveness induced by reactive oxygen species (ROS).

Albina JE, Abate JA, Henry WL Jr (1991) Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: role of IFN-gamma in the induction of the nitric oxide-synthesizing pathway. J Immunol 147:144PubMed

Allison J, Georgiou HM, Strasser A, Vaux DL (1997) Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci U S A 94:3943CrossRefPubMed

Aoe T, Okamoto Y, Saito T (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881CrossRefPubMed

Arai H, Gordon D, Nabel EG, Nabel GJ (1997) Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 94:13862CrossRefPubMed

Arista MC, Callopoli A, De Franceschi L et al (1994) Flow cytometric study of lymphocyte subsets in patients at different stages of colorectal carcinoma. Dis Colon Rectum 37:S30PubMed

Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 99:931CrossRefPubMed

Babior BM, Kipnes RS, Curnutte JT (1973) Biological defense mechanisms: the production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 52:741

Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141PubMed

Beharka A, Redican S, Leka L, Meydani SN (1997) Vitamin E status and immune function. Methods Enzymol 282:247CrossRefPubMed

10.

Bendandi M, Gocke CD, Kobrin CB et al (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5:1171CrossRefPubMed

11.

Biaglow JE, Mitchell JB, Held K (1992) The importance of peroxide and superoxide in the X-ray response. Int J Radiat Oncol Biol Phys 22:665PubMed

12.

Biesalski HK (2002) Meat and cancer: meat as a component of a healthy diet. Eur J Clin Nutr 56[Suppl 1]:S2CrossRef

13.

Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254CrossRefPubMed

14.

Birkeland ML, Johnson P, Trowbridge IS, Pure E (1989) Changes in CD45 isoform expression accompany antigen-induced murine T-cell activation. Proc Natl Acad Sci U S A 86:6734PubMed

15.

Blanchetot C, Tertoolen LG, den Hertog J (2002) Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress. Embo J 21:493CrossRefPubMed

16.

Brentjens RJ, Latouche JB, Santos E et al (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279CrossRefPubMed

17.

Burnet FM (1957) Cancer—a biological approach. BMJ i:841

18.

Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1PubMed

19.

Caselli A, Marzocchini R, Camici G et al (1998) The inactivation mechanism of low molecular weight phosphotyrosine-protein phosphatase by H2O2. J Biol Chem 273:32554CrossRefPubMed

20.

Cemerski S, van Meerwijk JP, Romagnoli P (2003) Oxidative-stress-induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules. Eur J Immunol 33:2178CrossRefPubMed

21.

Childs R, Chernoff A, Contentin N et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750CrossRefPubMed

22.

Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI (1999) Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163:507PubMed

23.

Colonna M, Samaridis J, Cella M et al (1998) Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 160:3096PubMed

24.

Davidson WF, Giese T, Fredrickson TN (1998) Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 187:1825CrossRefPubMed

25.

De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M (1997) Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 27:1229PubMed

26.

DeFrancesco L (2001) Prostate cancer prevention trial launched. Nat Med 7:1076CrossRef

27.

Devadas S, Zaritskaya L, Rhee SG, Oberley L, Williams MS (2002) Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. J Exp Med 195:59CrossRefPubMed

28.

Dianzani U, Luqman M, Rojo J et al (1990) Molecular associations on the T cell surface correlate with immunological memory. Eur J Immunol 20:2249PubMed

29.

Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190:1025CrossRefPubMed

30.

Dornan S, Sebestyen Z, Gamble J et al (2002) Differential association of CD45 isoforms with CD4 and CD8 regulates the actions of specific pools of p56lck tyrosine kinase in T cell antigen receptor signal transduction. J Biol Chem 277:1912CrossRefPubMed

31.

Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850CrossRefPubMed

32.

Dummer W, Niethammer AG, Baccala R et al (2002) T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 110:185CrossRefPubMed

33.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991CrossRefPubMed

34.

Dutoit V, Taub RN, Papadopoulos KP et al (2002) Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110:1813CrossRefPubMed

35.

Eaton JD, Perry MJ, Nicholson S et al (2002) Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 89:19CrossRefPubMed

36.

Edinger M, Hoffmann P, Ermann J et al (2003) CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9:1144CrossRefPubMed

37.

Ehrlich P (1909) Ueber den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 5

38.

Engleman EG (2003) Dendritic cell-based cancer immunotherapy. Semin Oncol 30:23CrossRef

39.

Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B (2000) Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 164:5023PubMed

40.

Fontana A, Frei K, Bodmer S et al (1989) Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 143:3230PubMed

41.

Fournel S, Aguerre-Girr M, Huc X et al (2000) Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 164:6100PubMed

42.

Fruh K, Ahn K, Djaballah H et al (1995) A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415CrossRefPubMed

43.

Gackowski D, Banaszkiewicz Z, Rozalski R, Jawien A, Olinski R (2002) Persistent oxidative stress in colorectal carcinoma patients. Int J Cancer 101:395CrossRefPubMed

44.

Garrido F, Festenstein H, Schirrmacher V (1976) Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature 261:705PubMed

45.

Garrido F, Ruiz-Cabello F, Cabrera T et al (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89CrossRefPubMed

46.

Gaschen B, Taylor J, Yusim K et al (2002) Diversity considerations in HIV-1 vaccine selection. Science 296:2354CrossRefPubMed

47.

Gilboa E (1999) The makings of a tumor rejection antigen. Immunity 11:263CrossRefPubMed

48.

Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52:6949PubMed

49.

Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189PubMed

50.

Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734CrossRefPubMed

51.

Gross L (1943) Intradermal immunisation of C3H mice against a sarcoma that origintated in an animal of the same line. Cancer Res 3:326

52.

Hahne M, Rimoldi D, Schroter M et al (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363CrossRefPubMed

53.

Heinonen OP, Albanes D, Virtamo J et al (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440CrossRefPubMed

54.

Hellstrand K, Hermodsson S (1986) Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol 137:656PubMed

55.

Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82:1009CrossRefPubMed

56.

Hersey P, Zhang XD (2001) How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 1:142CrossRefPubMed

57.

Heslop HE, Ng CY, Li C et al (1996) Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551PubMed

58.

Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357CrossRefPubMed

59.

Ibrahim EC, Guerra N, Lacombe MJ et al (2001) Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61:6838PubMed

60.

Ikeda H, Lethe B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199CrossRefPubMed

61.

Jin YJ, Friedman J, Burakoff SJ (1998) Regulation of tyrosine phosphorylation in isolated T cell membrane by inhibition of protein tyrosine phosphatases. J Immunol 161:1743PubMed

62.

Kambayashi T, Michaelsson J, Fahlen L et al (2001) Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro. Eur J Immunol 31:869CrossRefPubMed

63.

Kandil A, Bazarbashi S, Mourad WA (2001) The correlation of Epstein-Barr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing Hodgkin disease. Cancer 91:1957CrossRefPubMed

64.

Kemp RA, Ronchese F (2001) Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 167:6497PubMed

65.

Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999CrossRefPubMed

66.

Kiessling R, Wasserman K, Horiguchi S et al (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353CrossRefPubMed

67.

Kirchner H, Chused TM, Herberman RB, Holden HT, Lavrin DH (1974) Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med 139:1473CrossRefPubMed

68.

Klein G (1973) Immunological surveillance against neoplasia. Harvey Lect 69:71–102PubMed

69.

Koh CY, Blazar BR, George T et al (2001) Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97:3132CrossRefPubMed

70.

Koike M, Sekigawa I, Okada M et al (2002) Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res 26:705CrossRefPubMed

71.

Kolenko V, Wang Q, Riedy MC et al (1997) Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 159:3057PubMed

72.

Kono K, Ressing ME, Brandt RM et al (1996) Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2:1825PubMed

73.

Kono K, Salazar-Onfray F, Petersson M et al (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308PubMed

74.

Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266PubMed

75.

Lanier LL (1998) NK cell receptors. Annu Rev Immunol 16:359CrossRefPubMed

76.

Leek RD, Harris AL, Lewis CE (1994) Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 56:423PubMed

77.

Lefebvre S, Antoine M, Uzan S et al (2002) Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196:266CrossRefPubMed

78.

Lehmann F, Marchand M, Hainaut P et al (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340PubMed

80.

Leitenberg D, Novak TJ, Farber D, Smith BR, Bottomly K (1996) The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation. J Exp Med 183:249CrossRefPubMed

79.

Leitenberg D, Boutin Y, Lu DD, Bottomly K (1999) Biochemical association of CD45 with the T cell receptor complex: regulation by CD45 isoform and during T cell activation. Immunity 10:701CrossRefPubMed

81.

Levitskaya J, Coram M, Levitsky V et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. Nature 375:685CrossRefPubMed

82.

Liang B, Chung S, Araghiniknam M, Lane LC, Watson RR (1996) Vitamins and immunomodulation in AIDS. Nutrition 12:1CrossRefPubMed

83.

Liebler DC (1993) The role of metabolism in the antioxidant function of vitamin E. Crit Rev Toxicol 23:147PubMed

84.

Lin MT, Tseng LH, Frangoul H et al (2000) Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation. Blood 95:3832PubMed

85.

Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756PubMed

86.

Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition [see comments]. Immunol Today 11:237CrossRefPubMed

87.

Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS (1999) Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163:6251PubMed

88.

Long EO, Rajagopalan S (2002) Stress signals activate natural killer cells. J Exp Med 196:1399CrossRefPubMed

89.

Malmberg KJ, Arulampalam V, Ichihara F et al (2001) Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol 167:2595PubMed

90.

Malmberg KJ, Lenkei R, Petersson M et al (2002) A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res 8:1772PubMed

91.

Malmberg KJ, Levitsky V, Norell H et al (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110:1515CrossRefPubMed

92.

Marincola FM, Shamamian P, Simonis TB et al (1994) Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emph Tumor Immunol 16:13

93.

Marrack P, Bender J, Hildeman D et al (2000) Homeostasis of alpha beta TCR+ T cells. Nat Immunol 1:107CrossRefPubMed

94.

Matsuda M, Petersson M, Lenkei R et al (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765PubMed

96.

Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R (1999) Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190:1033CrossRefPubMed

95.

Medema JP, de Jong J, Peltenburg LT et al (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98:11515CrossRefPubMed

97.

Medema JP, Schuurhuis DH, Rea D et al (2001) Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 194:657CrossRefPubMed

98.

Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188:177CrossRefPubMed

99.

Meydani SN, Meydani M, Blumberg JB et al (1997) Vitamin E supplementation and in vivo immune response in healthy elderly subjects: a randomized controlled trial. JAMA 277:1380CrossRef

100.

Michaelsson J, Teixeira De Matos C, Achour A, Lanier LL, Karre K, Soderstrom K (2002) A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 196:1403CrossRefPubMed

101.

Mizoguchi H, O’Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795PubMed

102.

Mizutani H, Tada-Oikawa S, Hiraku Y, Oikawa S, Kojima M, Kawanishi S (2002) Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide. J Biol Chem 277:30684CrossRefPubMed

103.

Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein–Barr virus gene BCRFI. Science 248:1230PubMed

104.

Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA (1998) Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160:643PubMed

105.

Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ (1997) T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40:113PubMed

106.

Naito Y, Saito K, Shiiba K et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491PubMed

107.

Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328PubMed

108.

Novak TJ, Farber D, Leitenberg D, Hong SC, Johnson P, Bottomly K (1994) Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity 1:109CrossRefPubMed

109.

Odeleye OE, Watson RR (1991) The potential role of vitamin E in the treatment of immunologic abnormalities during acquired immune deficiency syndrome. Prog Food Nutr Sci 15:1PubMed

110.

Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693CrossRefPubMed

111.

Paul P, Cabestre FA, Le Gal FA et al (1999) Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 59:1954PubMed

113.

Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J (2000) Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog 11:97PubMed

112.

Pawelec G, Barnett Y, Forsey R et al (2002) T cells and aging, January 2002 update. Front Biosci 7:d1056PubMed

114.

Pericle F, Kirken RA, Bronte V, Sconocchia G, DaSilva L, Segal DM (1997) Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J Immunol 159:2580PubMed

115.

Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137PubMed

116.

Pisa P, Halapi E, Pisa EK et al (1992) Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A 89:7708PubMed

117.

Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL (1998) Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101:2579

118.

Ramal LM, Maleno I, Cabrera T et al (2000) Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 61:1001CrossRefPubMed

119.

Restifo NP (2000) Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6:493CrossRefPubMed

120.

Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100PubMed

121.

Reth M (2002) Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 3:1129CrossRefPubMed

122.

Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68CrossRefPubMed

123.

Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281CrossRefPubMed

125.

Rosenberg SA, Yang JC, Topalian SL et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907CrossRefPubMed

124.

Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321PubMed

126.

Rosenberg SA, Yang JC, White DE, Steinberg SM (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228:307CrossRefPubMed

127.

Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK (2002) Epstein–Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99:2009CrossRefPubMed

128.

Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097CrossRefPubMed

129.

Rygaard J, Povlsen CO (1974) The mouse mutant nude does not develop spontaneous tumours: an argument against immunological surveillance. Acta Pathol Microbiol Scand [B] Microbiol Immunol 82:99

130.

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151

131.

Salazar-Onfray F, Charo J, Petersson M et al (1997) Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 159:3195PubMed

132.

Salvadori S, Martinelli G, Zier K (2000) Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164:2214PubMed

133.

Santin AD, Hermonat PL, Ravaggi A et al (2001) Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 51:254CrossRefPubMed

134.

Schmidt KN, Amstad P, Cerutti P, Baeuerle PA (1996) Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappa B. Adv Exp Med Biol 387:63PubMed

135.

Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61:4756PubMed

136.

Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. Embo J 10:2247PubMed

137.

Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305–334CrossRefPubMed

138.

Seaman WE, Gindhart TD, Blackman MA, Dalal B, Talal N, Werb Z (1981) Natural killing of tumor cells by human peripheral blood cells: suppression of killing in vitro by tumor-promoting phorbol diesters. J Clin Invest 67:1324

139.

Seliger B, Maeurer MJ, Ferrone S (1997) TAP off—tumors on. Immunol Today 18:292CrossRefPubMed

140.

Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455CrossRefPubMed

141.

Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211PubMed

142.

Shin MS, Park WS, Kim SY et al (1999) Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 154:1785PubMed

143.

Shlomchik WD, Couzens MS, Tang CB et al (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:412CrossRefPubMed

144.

Spaggiari GM, Contini P, Dondero A et al (2002) Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 100:4098CrossRefPubMed

145.

Stutman O (1974) Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183:534PubMed

146.

Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51:794PubMed

147.

Takeda K, Hayakawa Y, Smyth MJ et al (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94CrossRefPubMed

148.

Tanaka J, Fujiwara H, Torisu M (1979) Vitamin E and immune response, I: enhancement of helper T cell activity by dietary supplementation of vitamin E in mice. Immunology 38:727PubMed

149.

Teshima T, Mach N, Hill GR et al (2001) Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 61:162PubMed

150.

Thomas L (1959) Cellular and humoral aspects of the hypersensitive states. Hoeber-Harper, New York

151.

Thurner B, Haendle I, Roder C et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669CrossRefPubMed

152.

Timmerman JM, Singh G, Hermanson G et al (2002) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62:5845PubMed

153.

Toes RE, Hoeben RC, van der Voort EI et al (1997) Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci U S A 94:14660CrossRefPubMed

154.

Trapani JA, Sutton VR, Smyth MJ (1999) CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today 20:351CrossRefPubMed

155.

Trowbridge IS, Thomas ML (1994) CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 12:85CrossRefPubMed

156.

Turley SJ (2002) Dendritic cells: inciting and inhibiting autoimmunity. Curr Opin Immunol 14:765CrossRefPubMed

157.

Urban JL, Holland JM, Kripke ML, Schreiber H (1982) Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J Exp Med 156:1025CrossRefPubMed

158.

Uyttenhove C, Van Snick J, Boon T (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815, I: rejection by syngeneic mice. J Exp Med 152:1175CrossRefPubMed

159.

Uzzo RG, Clark PE, Rayman P et al (1999) Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 91:718CrossRefPubMed

160.

Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL (1999) Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. Embo J 18:4250CrossRefPubMed

161.

Van der Bruggen P, Traversari C, Chomez P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643PubMed

162.

Van Pel A, Boon T (1982) Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A 79:4718PubMed

163.

Vaux DL (1995) Immunology: ways around rejection. Nature 377:576

164.

Wang RF (2002) Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 188:65CrossRefPubMed

165.

Woo EY, Chu CS, Goletz TJ et al (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766PubMed

166.

Xu Z, Weiss A (2002) Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol 3:764CrossRefPubMed

167.

Yamagishi H, Pellis NR, Macek C, Kahan BD (1980) Changes in spleen morphology and lymphoid cell activity during tumor progression. Eur J Cancer 16:1417CrossRefPubMed

168.

Yee C, Thompson JA, Byrd D et al (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99:16168CrossRefPubMed

169.

Yewdell JW, Hill AB (2002) Viral interference with antigen presentation. Nat Immunol 3:1019CrossRefPubMed

170.

Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP (1999) Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 162:3273PubMed

171.

Zinkernagel RM (2001) Immunity against solid tumors? Int J Cancer 93:1CrossRefPubMed

Titel: Effective immunotherapy against cancer
A question of overcoming immune suppression and immune escape?
verfasst von: Karl-Johan Malmberg
Publikationsdatum: 01.10.2004
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 10/2004
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0577-x

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Effective immunotherapy against cancer

A question of overcoming immune suppression and immune escape?

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2004

Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy

Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword?

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape

The paradox of T cell–mediated antitumor immunity in spite of poor clinical outcome in human melanoma

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression

Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie